In this edition:
Mosunetuzumab in high-risk, heavily pre-treated RR-FL
Axicabtagene ciloleucel for RR-PMBCL
SEQUOIA: zanubrutinib + venetoclax for treatment-naïve CLL/SLL with del(17P) and/or TP53 alterations
ASC4FIRST: asciminib vs. TKIs in newly diagnosed CML
PhALLCON: in-depth responder subgroup analysis
AUGMENT-101: revumenib monotherapy in relapsed/refractory KMT2A-rearranged acute leukaemia
IMROZ: isatuximab + VRd in transplant-ineligible, newly diagnosed multiple myeloma
JAK2V617F molecular response & EFS in early polycythaemia vera
Auto- vs. allo-SCT in T-cell lymphoma
HD21: BrECADD vs. BEACOPP for advanced-stage classical Hodgkin lymphoma
Please login below to download this issue (PDF)